Posted inAllergy & Immunology news Respiratory
ICS–Formoterol Users Show Lower Reported Adherence but Less SABA Use: Real‑World Evidence from the MASK‑air Asthma App
Analysis of MASK‑air app data from 2015–2022 found lower self‑reported adherence to ICS+formoterol versus other ICS+LABA combinations, but paradoxically lower short‑acting β2‑agonist (SABA) use and similar symptom control in ICS+formoterol users.